News Releases - 2012

8 MAY 2012　[Pharmaceuticals]

• The Federal Circuit Decision Affirming the Validity of the Asserted Claims of Otsuka’s Patent to ABILIFY®

8 MAY 2012　[Pharmaceuticals]

• Results from a Phase 3 Study of Once-monthly Aripiprazole Intramuscular (IM) Depot Formulation for the Maintenance Treatment of Schizophrenia Presented at APA Annual Meeting

17 APR 2012　[Pharmaceuticals]

• New Antipsychotic Agent "ABILIFY® OD Tablets" Pursues Agreeability for Patients, Enables easy Adherence

27 MAR 2012　[Nutraceuticals]

• Gerlinéa to Launch Nationwide −Enjoyable Calorie Control without Giving Up Sweetness−

16 MAR 2012　[Nutraceuticals]

• Breaking Conventional Rules of Snack Foods, Healthy and Innovative Soy Snack "SoyCarat" Debuts

13 MAR 2012　[Corporate]

• Otsuka America Announces Personnel Changes[PDF:182KB]

5 MAR 2012　[Nutraceuticals]

• Otsuka Pharmaceutical Releases its UL・OS Brand of Men’s Cosmetics in South Korea
  First overseas market for the brand after it was launched in Japan three and a half years ago

27 FEB 2012　[Nutraceuticals]

• Otsuka Pharmaceutical Supports the Tokyo Marathon for Six Years Running with Amino-Value
  Supporting the efforts of over 200,000 runners

10 FEB 2012　[Corporate]

• Heartful Kawauchi Co., Ltd., A Promoter of Employment for Persons with Disabilities, Receives Authorization as Special Subsidiary Company

1 FEB 2012　[Corporate]

• Otsuka Pharmaceutical's Fukuroi Factory Receives FY2011 METI Minister Award for Factories Making an Outstanding Contribution to the Environment

18 JAN 2012　[Pharmaceuticals]

• Antipsychotic Agent ABILIFY® Receives Regulatory Approvals for Additional Indication "Improvement of Manic Symptoms Associated with Bipolar Disorder" and for New Dosage Form "ABILIFY® OD Tablets"

13 JAN 2012　[Pharmaceuticals]

• Otsuka Pharmaceutical Files New Drug Application for The Dopamine Agonist Transdermal Patch, Rotigotine Patch, in Japan

13 JAN 2012　[Pharmaceuticals]

• Otsuka Pharmaceutical and UCB focus collaboration in the area of Central Nervous System (CNS) disorders

5 JAN 2012　[Pharmaceuticals]

• Mucosta® ophthalmic suspension UD2% releases on January 5, 2012